Vasa vasorum in plaque angiogenesis, metabolic syndrome, type 2 diabetes mellitus, and atheroscleropathy: A malignant transformation

Cardiovascular Diabetology

Volumn 3, Issue , 2004, Pages

  Hayden, Melvin R ^a   Tyagi, Suresh C ^b  

^a UNIVERSITY OF MISSOURI   (United States)

^b University of Louisville School of Medicine   (United States)

Author keywords

Arteriogenesis; eNOS; Nitric oxide (eNO); Reactive nitrogen species (RNS); Reactive oxygen species (ROS); Reactive thiol species (RTS)

Indexed keywords

REACTIVE OXYGEN METABOLITE;

ANGIOGENESIS; ATHEROMA; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; BLEEDING; CARDIOVASCULAR RISK; CHRONIC INFLAMMATION; DISEASE ASSOCIATION; HEART MUSCLE ISCHEMIA; HUMAN; MALIGNANT TRANSFORMATION; METABOLIC SYNDROME X; MORBIDITY; MORTALITY; NEOVASCULARIZATION (PATHOLOGY); NON INSULIN DEPENDENT DIABETES MELLITUS; OXIDATION REDUCTION REACTION; REVIEW; RISK ASSESSMENT; RISK REDUCTION; VASA VASORUM; VASCULARIZATION;

EID: 2942549547     PISSN: 14752840     EISSN: None     Source Type: Journal    
DOI: 10.1186/1475-2840-3-1     Document Type: Review

References (48)

1. Acierno LJ: Atherosclerosis (arteriosclerosis). In The History of Cardiology Edited by: Acierno LJ. New York: Parthenon Publishing Group Inc; 1994:109-126.
2. Ross R: Atherosclerosis - an inflammatory disease. N Engl J Med 1999, 340(2):115-126.
3. Ridker PM, Morrow DA: C-reactive protein, inflammation, and coronary risk. Cardiol Clin 2003, 21(3):315-325.
4. Isner JM: Cancer and atherosclerosis: the broad mandate of angiogenesis. Circulation 1999, 99:1653-1655.
5. Folkman J: Tumor angiogenesis: therapeutic implications. N Engl J Med 1971, 285(21):1182-1186.
6. Hayden MR, Tyagi SC: Atherosclerosis: Implications of angiotensin II and the AT-1 receptor. In Angiotensin II Blockade: Physiological and Clinical Implications Edited by: Dhalla NS, Zahradka P, Dixon IMC, and Beamish RE. Boston MA. Kluwer Academic Publishers; 1998:233-243.
7. Hayden MR, Tyagi SC: Arterial vascular remodeling: The endothelial cell's central role. Missouri Medicine 1998, 95(5):213-217.
8. Hayden MR, Tyagi SC: Intimal redox stress: Accelerated atherosclerosis in metabolic syndrome and type 2 diabetes mellitus. Atheroscleropathy. Cardiovasc Diabetol 2002, 1(1):3.
9. Hayden MR, Tyagi SC: Is type 2 diabetes mellitus a vascular disease (atheroscleropathy) with hyperglycemia a late manifestation? The role of NOS, NO, and redox stress. Cardiovasc Diabetol 2(1):2.
10. Hayden MR, Tyagi SC: Arteriogenesis: Angiogenesis within Unstable Atherosclerotic Plaque - Interactions with Extracellular Matrix. Curr Interv Cardiol Rep 2000, 2(3):218-227.
11. Strong JP, Malcom GT, McMahan CA, Tracy RE, Newman WP 3rd, Herderick EE, Cornhill JF: Prevalence and extent of atherosclerosis in adolescents and young adults: implications for prevention from the Pathobiological Determinants of Atherosclerosis in Youth Study. JAMA 1999, 281(8):727-735.
12. Enos WF, Holmes RH, Beyer J: Landmark article, July 18, 1953: Coronary disease among United States soldiers killed in action in Korea. Preliminary report. JAMA 1986, 256(20):2859-2862.
13. Williams JK, Heistad DD: [The vasa vasorum of the arteries]. J Mal Vasc 1996, 21(Suppl C):266-269.
14. Williams KJ, Tabas I: The response-to-retention hypothesis of early atherogenesis. Arterioscler Thromb Vasc Biol 1995, 15(5):551-561.
15. Williams KJ, Tabas I: The response-to-retention hypothesis of atherogenesis reinforced. Curr Opin Lipidol 1998, 9(5):471-474.
16. Lee RT, Libby P: The unstable atheroma. Arterioscler Thromb Vasc Biol 1997, 17(10):1859-1867.
17. Barger AC, Beeuwkes R 3rd, Lainey LL, Silverman KJ: Hypothesis: vasa vasorum and neovascularization of human coronary arteries. A possible role in the pathophysiology of atherosclerosis. N Engl J Med 1984, 310(3):175-177.
18. Barger AC, Beeuwkes R 3rd: Rupture of coronary vasa vasorum as a trigger of acute myocardial infarction. Am J Cardiol 1990, 66(16):41G-43G.
19. Kumamoto M, Nakashima Y, Sueishi K: Intimal neovascularization in human coronary atherosclerosis: Its origin and pathophysiological significance. Human Pathology 1995, 26:450-456.
20. Fuster V, Corti R, Badimon JJ: The Mikamo Lecture 2002. Therapeutic targets for the treatment of atherothrombosis in the new millennium - clinical frontiers in atherosclerosis research. Circ J 2002, 66(9):783-790.
21. Purushothaman KR, Fuster V, O'Connor WN, Moreno PR: Neovascularization is the most powerful independent predictor for progression to disruption in high-risk atherosclerotic plaques. J Am Coll Cardiol 2003, 41(6 Suppl B):352-353.
22. Pugh CW, Ratcliffe PJ: Regulation of angiogenesis by hypoxia: role of the HIF system. Nat Med 2003, 9(6):677-684.
23. Williamson JR, Kilo C: Hyperglycemia "pseudohypoxia" and diabetic complications. Diabetes 1993, 42:801-813.
24. Zhang Y, Cliff WJ, Schoefl GI, Higgins G: Immunohistochemical study of intimal microvessels in coronary atherosclerosis. Am J Pathol 1993, 143:164-172.
25. Kolodgie FD, Gold HK, Burke AP, Fowler DR, Kruth HS, Weber DK, Farb A, Guerrero LJ, Hayase M, Kutys R, Narula J, Finn AV, Virmani R: Intraplaque hemorrhage and progression of coronary atheroma. N Engl J Med 2003, 349(24):2316-2325.
26. Libby P: Molecular bases of the acute coronary syndromes. Circulation 1995, 91(11):2844-2850.
27. Lafont A, Libby P: The smooth muscle cell: sinner or saint in restenosis and the acute coronary syndromes? J Am Coll Cardiol 1998, 32(1):283-2855.
28. Kwon HM, Sangiorgi G, Ritman EL, McKenna C, Holmes DR Jr, Schwartz RS, Lerman A: Enhanced coronary vasa vasorum neovascularization in experimental hypercholesterolemia. J Clin Invest 1998, 101(8):1551-1556.
29. Kantor B, Kwon HM, Ritman EL, Holmes DR, Schwartz RS: Images in Cardiology Imaging the coronary microcirculation: 3D micro-CT of coronary vasa vasorum. Int J Cardiovasc Intervent 1999, 2(1):79.
30. Burke AP, Farb A, Malcom GT, Liang Y, Smialek JE, Virmani R: Plaque rupture and sudden death related to exertion in men with coronary artery disease. JAMA 1999, 281(10):921-926.
31. O'Brien KD, McDonald TO, Chait A, Allen MD, Alpers CE: Neovascular expression of E-selectin, intercellular adhesion molecule-1, and vascular cell adhesion molecule-1 in human atherosclerosis and their relation to intimal leukocyte content. Circulation 1996, 93(4):672-682.
32. de Boer OJ, van der Wal AC, Teeling P, Becker AE: Leucocyte recruitment in rupture prone regions of lipid-rich plaques: a prominent role for neovascularization? Cardiovasc Res 1999, 41(2):443-449.
33. Muller JE, Abela GS, Nesto RW, Tofler GH: Triggers, acute risk factors and vulnerable plaques: the lexicon of a new frontier. J Am Coll Cardiol 1994, 23(3):809-813.
34. Stefanadis C, Diamantopoulos L, Dernellis J, Economou E, Tsiamis E, Toutouzas K, Vlachopoulos C, Toutouzas P: Heat production of atherosclerotic plaques and inflammation assessed by the acute phase proteins in acute coronary syndromes. J Mol Cell Cardiol 2000, 32(1):43-52.
35. Madjid M, Naghavi M, Malik BA, Litovsky S, Willerson JT, Casscells W: Thermal detection of vulnerable plaque. Am J Cardiol 2002, 90(10C):36L-39L.
36. Abaci A, Oguzhan A, Kahraman S, Eryol NK, Unal S, Arinc H, Ergin A: Effect of diabetes mellitus on formation of coronary collateral vessels. Circulation 1999, 99(17):2239-42.
37. Waltenberger J: Impaired collateral vessel development in diabetes: potential cellular mechanisms and therapeutic implications. Cardiovasc Res 2001, 49(3):554-560.
38. Waltenberger J, Lange J, Kranz A: Vascular endothelial growth factor-A-induced chemotaxis of monocytes is attenuated in patients with diabetes mellitus: A potential predictor for the individual capacity to develop collaterals. Circulation 2000, 102(2):185-190.
39. Panutsopulos D, Zafiropoulos A, Krambovitis E, Kochiadakis GE, Igoumenidis NE, Spandidos DA: Peripheral monocytes from diabetic patients with coronary artery disease display increased bFGF and VEGF mRNA expression. J Transl Med 2003, 1(1):6.
40. Tyagi SC, Kumar S, Cassatt S, Parker JL: Temporal expression of extracellular matrix metalloproteinases and tissue plasminogen activator in the development of collateral vessels in the canine model of coronary occlusion. Can J Physiol Pharmacol 1996, 74(8):983-995.
41. Schaper W, Scholz D: Factors regulating arteriogenesis. Arterioscler Thromb Vasc Biol 2003, 23(7):1143-1151.
42. Prior BM, Lloyd PG, Ren J, Li Z, Yang HT, Laughlin MH, Terjung RL: Arteriogenesis: role of nitric oxide. Endothelium 2003, 10:207-216.
43. Warltier DC, Weihrauch DW, Moniz M, Tessmer J, Chilian WM: Ischemia-induced coronary collateral growth is dependent on vascular endothelial growth factor and nitric oxide. Circulation 2000, 102(25):3098-3103.
44. Brevetti LS, Chang DS, Tang GL, Sarkar R, Messina LM: Overexpression of endothelial nitric oxide synthase increases skeletal muscle blood flow and oxygenation in severe rat hind limb ischemia. J Vasc Surg 2003, 38(4):820-826.
45. Yang HT, Yan Z, Abraham JA, Terjung RL: VEGF(121)- and bFGF-induced increase in collateral blood flow requires normal nitric oxide production. Am J Physiol Heart Circ Physiol 2001, 280(3):H1097-H1104.
46. Sukhova GK, Williams JK, Libby P: Statins reduce inflammation in atheroma of nonhuman primates independent of effects on serum cholesterol. Arterioscler Thromb Vasc Biol 2002, 22(9):1452-1458.
47. Moulton KS: Plaque angiogenesis and atherosclerosis. Curr Atheroscler Rep 2001, 3(3):225-233.
48. Moulton KS, Vakili K, Zurakowski D, Soliman M, Butterfield C, Sylvin E, Lo KM, Gillies S, Javaherian K, Folkman J: Inhibition of plaque neovascularization reduces macrophage accumulation and progression of advanced atherosclerosis. Proc Natl Acad Sci U S A 2003, 100(8):4736-4741.